Slavin K V, Vannemreddy P S S V, Goellner E, Alaraj A M, Aydin S, Eboli P, Mlinarevich N, Watson K S, Walters L E, Amin-Hanjani S, Deveshwar R, Aletich V, Charbel F T
Department of Neurosurgery, University of Illinois at Chicago; Chicago, Illinois, USA -
Neuroradiol J. 2011 Mar 29;24(1):131-5. doi: 10.1177/197140091102400119. Epub 2011 Apr 5.
Based on past laboratory and anecdotal clinical experience, we hypothesized that prolonged cervical spinal cord stimulation (SCS) in the acute settings of aneurysmal subarachnoid hemorrhage (aSAH) would be both safe and feasible, and that 2-week stimulation will reduce incidence of cerebral arterial vasospasm. The goal of our clinical study was to establish feasibility and safety of cervical SCS in a small group of selected aSAH patients. Single-arm non-randomized prospective study of cSCS in aSAH patients involved percutaneous implantation of 8-contact electrode in 12 consecutive aSAH patients that satisfied strict inclusion criteria. The electrode insertion was performed immediately upon surgical or endovascular securing of the ruptured aneurysm while the patient was still under general anesthesia. Patients were stimulated for 14 consecutive days or until discharge. There were no complications related to the electrode insertion or to SCS during the study and no long-term side effects of SCS during 1-year follow-up. There was 1 unrelated death and two electrode pullouts. This article summarizes technical details of SCS electrode insertion and the stimulation parameters used in the research study. Our study of SCS for prevention of vasospasm after aSAH conclusively shows both safety and feasibility of this promising treatment approach. Despite high level of acuity in aSAH patients, impaired level of consciousness, frequent patient re-positioning, need in multiple tests and variety of monitors, SCS electrodes may be safely implanted and maintained for the two-week period. Long-term follow up shows no adverse effects of cervical SCS in this patient category.
基于过去的实验室研究和临床经验,我们推测在动脉瘤性蛛网膜下腔出血(aSAH)的急性期延长颈脊髓刺激(SCS)是安全可行的,并且两周的刺激将降低脑动脉血管痉挛的发生率。我们临床研究的目的是在一小部分选定的aSAH患者中确定颈SCS的可行性和安全性。对aSAH患者进行颈SCS的单臂非随机前瞻性研究,包括对12例连续的aSAH患者经皮植入8触点电极,这些患者均符合严格的纳入标准。电极插入在破裂动脉瘤经手术或血管内固定后立即进行,此时患者仍处于全身麻醉状态。患者连续接受14天刺激或直至出院。研究期间未出现与电极插入或SCS相关的并发症,1年随访期间也未出现SCS的长期副作用。有1例无关死亡和2例电极拔出。本文总结了SCS电极插入的技术细节以及研究中使用的刺激参数。我们对SCS预防aSAH后血管痉挛的研究最终表明了这种有前景的治疗方法的安全性和可行性。尽管aSAH患者病情严重、意识水平受损、患者频繁重新定位、需要进行多项检查和使用各种监测设备,但SCS电极仍可安全植入并维持两周。长期随访显示,该类患者中颈SCS无不良反应。